Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States

Mycoses

Volumn 54, Issue 5, 2011, Pages

  Kim, Aryun ^a   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Antifungal; Aspergillosis; Cost; Economics; Mortality

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; VORICONAZOLE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG COST; FEMALE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; INVASIVE ASPERGILLOSIS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; COHORT STUDIES; ECHINOCANDINS; FEMALE; HOSPITAL COSTS; HUMANS; INFUSIONS, INTRAVENOUS; INVASIVE PULMONARY ASPERGILLOSIS; LENGTH OF STAY; MALE; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES;

ASPERGILLUS;

EID: 80052800770     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01903.x     Document Type: Article

References (22)

1. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
2. Marr KA, Patterson T, Denning D. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16: 875-94.
3. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5: 26-34.
4. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000; 31: 1524-8.
5. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
6. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31: 1155-63.
7. Fleming RV, Kantarjian HM, Husni R et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001; 40: 511-20.
8. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56(Suppl S1): i17-i22.
9. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother 2005; 56(Suppl S1): i33-i38.
10. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
11. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
12. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6821 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37(Suppl.): 188-224.
13. Ament AJ, Hubben MWA, Verweij PE et al. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modeling approach. J Antimicrob Chemother 2007; 60: 385-93.
14. Slobbe L, Polinder S, Doorduijn JK et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008; 47: 1507-12.
15. Wenzel R, Favero AD, Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005; 55: 352-61.
16. Wingard JR, Herbrecht R, Mauskopf J, Schlamm HT, Marciniak A, Roberts CS. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis 2007; 9: 182-8.
17. Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008; 29: 160-9.
18. Baram D, Daroowalla F, Garcia R et al. Use of the All Patient Refined-Diagnosis Related Group (APR-DRG) Risk of Mortality Score as a severity adjustor in the medical ICU. Clin Med Circ Respir Pulmon Med 2008; 2: 19-25.
19. United States Department of Labor. Bureau of Labor Statistics. Consumer price index: annual percent change, us city average, medical care. [WWW document], September 2009. URL [accessed on 5 October 2009].
20. Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-84.
21. Tong KB, Lau CJ, Murtagh K, Layton AJ, Seifeldin AR. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis 2009; 13: 24-36.
22. Greene RE, Mauskopf J, Roberts CS, Zyczynski T, Schlamm HT. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis. Am J Health Syst Pharm 2007; 64: 2561-8.